• $4.1M
    Market Cap
  • -83.23%
    1-Year Change
  • Drug Manufacturers - Specialty & Generic
    Industry

Key Performance

More
  • Earnings Score: N/A
  • Momentum Score: 56
  • True Yield: N/A
  • Financial Health Score: N/A
TradeSmith Loading

Latest Research & News

Why Sunshine Biopharma (SBFM) Stock Dropped After Hours Today

Sunshine Biopharma (NASDAQ:SBFM) shares fell 5.17% to $0.30 in after-hours trading following the announcement of a one-for-ten reverse stock split effective June 1, 2026. The reverse split was undertaken to regain compliance with Nasdaq's minimum bid price requirement. The stock has declined 77.99% over the past 12 months and currently has a market capitalization of approximately $5.18 million.

05/29/2026, 2:16 AM • Benzinga

Peers

Statistics

More
Day Range
$2.46
$3.05
$2.60
1-Year Range
$0.25
$2.60
$2.60
Latest Close$2.60
Change
+$0.21 (+8.08%)
Volume13,312,240
Market Cap$4.1M
Shares Outstanding16.2M
P/E (TTM)-0.20
Diluted EPS (TTM)-$1.28
Enterprise Value-$2.8M

Information as of 06/02/2026

Company Profile

SUNSHINE BIOPHARMA INC
https://sunshinebiopharma.com
$4.1M
Market Cap
-$6.0M
Net Income
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
333 Las Olas Way, Fort Lauderdale, FL, United States, 33301
954 330 0684

Sunshine Biopharma, Inc. operates as a pharmaceutical company that engages in the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, dermatology, smoking cessation, cholelithiasis, anticonvulsant, urology, women's health, acid reflux, and anticonvulsant indications. Sunshine The company is based in Fort Lauderdale, Florida.

Key Executives

  • Steve N. Slilaty
  • Camille Sebaaly
  • Michel Roy
  • Robert G. Ferreira
  • Malek Chamoun

Current Ownership Distribution

  • Insiders243.1M (98.22%)
  • Institutions3.0M (1.23%)
  • Mutual Funds1.4M (0.55%)
  • Other0 (0.00%)